Variables | Mean ± SD Placebo (n = 21) | Mean ± SD Oleoylethanolamide (n = 22) | P1 | P2 |
---|---|---|---|---|
FBS (mg/dL) | ||||
Baseline | 114.75 ± 5.16 | 116.04 ± 4.57 | 0.394 | 0.394 |
End | 113.95 ± 5.43 | 101.681 ± 2.95 | 0.01 | 0.01 |
P3 | 0.401 | 0.01 | ||
Mean changes | − 0.8 ± 0.27 | − 14.35 ± 1.62 | 0.03 | 0.03 |
2hpp (mg/dL) | ||||
Baseline | 161 ± 9.14 | 162.50 ± 12.62 | 0.66 | 0.66 |
End | 159.05 ± 9.88 | 136.68 ± 10.94 | 0.01 | 0.01 |
P3 | 0.52 | 0.01 | ||
Mean changes | − 1.95 ± 0.73 | − 25.82 ± 1.68 | 0.041 | 0.041 |
HbA1c (%) | ||||
Baseline | 6.340 ± 0.565 | 6.486 ± 0.535 | 0.394 | 0.394 |
End | 6.250 ± 0.583 | 5.590 ± 0.361 | 0.01 | 0.01 |
P3 | 0.311 | 0.01 | ||
Mean changes | − 0.09 ± 0.02 | − 0.89 ± 0.17 | 0.02 | 0.02 |
Insulin (µU/ml) | ||||
Baseline | 12.37 ± 1.77 | 12.36 ± 1.73 | 0.378 | 0.378 |
End | 12.2 ± 1.75 | 10.12 ± 1.11 | 0.01 | 0.01 |
P3 | 0.329 | 0.01 | ||
Mean changes | − 0.17 ± 0.01 | − 2.24 ± 0.62 | 0.031 | 0.031 |
HOMA-IR | ||||
Baseline | 3.51 ± 0.64 | 3.546 ± 0.587 | 0.269 | 0.269 |
End | 3.44 ± 0.63 | 2.537 ± 0.287 | 0.01 | 0.01 |
P3 | 0.207 | 0.01 | ||
Mean changes | − 0.07 ± 0.01 | − 1.01 ± 0.3 | 0.038 | 0.038 |
CRP (µM) | ||||
Baseline | 7.99 ± 0.54 | 7.87 ± 0.52 | 0.46 | 0.46 |
End | 7.91 ± 0.59 | 7.03 ± 0.68 | 0.03 | 0.03 |
P3 | 0.39 | 0.034 | ||
Mean changes | − 0.08 ± 0.05 | − 0.84 ± 0.16 | 0.02 | 0.02 |